We’re excited to share our comprehensive whitepaper on Antibody-Drug Conjugates (ADCs), a groundbreaking class of targeted cancer therapies. Dive into the details and discover how ADCs are revolutionising oncology.
Here are some of the key highlights:
Mechanism of action
Learn how ADCs work as ‘trojan horses,’ delivering cytotoxic drugs directly to cancer cells while sparing healthy tissues.
FDA approvals
Explore the journey of 13 ADCs approved in the last twelve years for various cancers, including breast, lung, and ovarian cancer.
Pharma insights
Understand why ADCs are attracting substantial investment and collaboration in the pharmaceutical industry.
Future potential
Get a glimpse into the ongoing research and future applications of ADCs beyond oncology.
Click here to read the full whitepaper.
For an ABC of ADCs, click here to start with our introductory paper.
Get in touch:
Ed Corbett, Head of Consulting: [email protected]
Kaylie Fallon, Consultant: [email protected]
Shirley Shadur, Strategic Vice President: [email protected]